“I would like to thank Peter and Glenn for their dedication and contributions to the company as we worked through FDA clearance and commercial launch of gammaCore. They have been integral in advancing our pipeline and completing in our initial public offering,” commented Frank Amato, CEO of electroCore.
Dr. Fiorino will oversee the ongoing clinical development of the company’s gammaCore non-invasive vagus nerve stimulator into new potential indications, including migraine prevention and diseases of inflammation, such as rheumatoid arthritis. Posner will lead the financial planning, financial management and investor relations functions.
“Tony and Brian are both highly accomplished healthcare executives, and I look forward to their contributions as we continue executing on our gammaCore commercial growth plan,” said Amato. “I believe we have established a leadership team that will shepherd the company through its next phase of growth.”
Dr. Fiorino joins electroCore from Immune Pharma, where he served as interim CEO since August 2018. He joined Immune as chief medical officer and chief operating officer in August 2017 from Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, where he served as president and CEO.
Prior to joining Triumvira, Dr. Fiorino was CEO of BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases. Prior to joining BrainStorm, he was the founder, president and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through Phase 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup and Pequot Capital. Dr. Fiorino earned medical degree and a Ph.D. from the Albert Einstein College of Medicine and a bachelor of science degree from the Massachusetts Institute of Technology.
“I joined electroCore because I am excited by the potential of the company’s vagus nerve stimulation technology,” commented Dr. Fiorino. “I look forward to working with the team to accelerate the company’s clinical development plans and make this technology available to patients globally.”
Posner joins electroCore from Cellectar Biosciences, where he served as CFO since April 2018. Prior to Cellectar, he served in CFO roles at Alliqua BioMedical, Ocean Power Technologies and Power Medical Interventions. Earlier, Posner spent nine years at Pharmacopeia, where he rose from director of finance to CFO before the company was acquired by Ligand Pharmaceuticals. Prior to Pharmacopeia, he was CFO and vice president of operations at Photosynthetic Harvest, a startup biotechnology company, and regional CFO at Omnicare. Posner began his career as an audit supervisor at Coopers & Lybrand, which was subsequently merged to form PricewaterhouseCoopers.
“I am pleased to join the electroCore team at this pivotal time in the commercial roll-out and ongoing development of gammaCore,” said Posner. “The market opportunity for this technology is significant, and I believe the achievement of anticipated commercial and development milestones can yield significant shareholder value.”
electroCore Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.